FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
SALT LAKE CITY, Nov. 09, 2017 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the Jefferies Healthcare Conference at 8:40 a.m. GMT on November 16, 2017, at the Waldorf Hilton in London.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: stabilizing hereditary cancer revenue, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Media Contact: Ron Rogers
(801) 584-3065
[email protected]
Investor Contact: Scott Gleason
(801) 584-1143
[email protected]
